Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

This new article publication from Acta Pharmaceutica Sinica B, discusses how heme oxygenase 1-mediated ferroptosis in Kupffer ...

Halia plans to advance HT-6184 into a Phase 2 clinical trial for obesity later this year. This trial will evaluate the safety, tolerability, and efficacy of HT-6184 in combination with semaglutide for ...

About BioAegis BioAegis Therapeutics Inc. is a NJ-based clinical-stage, private company whose mission is to capitalize on a key component of the body's innate immune system, plasma gelsolin, to ...

BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its Co-founder, Steve Cordovano, ...

Shenzhen Zhongge Biotechnology Co. Ltd. has discovered NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, liver, cardiovascular, inflammatory, renal, metabolic and ...

NLRP3 is an inflammasome seeding pattern recognition receptor activated in response to multiple danger signals which perturb intracellular homeostasis. Electrostatic interactions between the NLRP3 ...

This study is a significant advancement in developing innovative therapies for neurodegenerative diseases, according to Zydus ...

Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for inflammatory and neurodegenerative diseases, today announced that ...